The concurrent use of anti-VEGF therapy can further remodel the tumor microenvironment by normalizing blood vessels, reducing infiltration of immune suppressor cells (e.g., Tregs, MDSCs), and enhance the sensitivity of tumor cells to immunotherapy, thus providing a strong biological rationale for this combined approach. This evidence concerns the gene VEGFA and neoplasm.